Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease

Cincinnati Children's Hospital Medical Center

Status: Enrolling

Conditions: Measles Vaccination; Sickle Cell Anemia; Sickle Cell Disease

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT07356050

VALID

Details and patient eligibility

About

The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)

Full description

Families of infants with SCD who are eligible for a measles vaccine per standard care will be contacted to discuss enrollment in the study. One cohort will be evaluated for response to the first measles vaccine (MV1) and another cohort will be evaluated for response to the second measles vaccine (MV2). Blood samples will be collected from participants prior to measles vaccination and then again at 4 and 8 weeks after vaccination.

Enrollment: 130 estimated patients

Sex: All

Ages: 6 months to 6 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Participants with confirmed Sickle Cell Disease.
2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
3. Willing and able to provide informed consent
4. Ability to comply with study related evaluations and follow-up visits.

Exclusion criteria

1. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.

Trial design

130 participants in 2 patient groups

Second Measles Vaccine (MV2)

Description:

Participants who receive second measles vaccine.

First Measles Vaccine (MV1)

Description:

Participants who obtain the first measles vaccine.